Evidence map›Paper›PMID 24198403›Full record

ArticleJournal of virology2014

Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication.

Angela M Mitchell, Matthew L Hirsch, Chengwen Li, R Jude Samulski

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Epigenetic regulation of transgenes.Journal of biotechnology · 2026
    Review
  2. Nuclear interferon-stimulated gene product maintains heterochromatin on the herpes simplex viral genome to limit lytic infection.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  3. Article
  4. SUMOylation in Viral Replication and Antiviral Defense.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  5. Intracellular Antiviral Immunity.Advances in virus research · 2018
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Diverse mechanisms evolved by DNA viruses to inhibit early host defenses.Critical reviews in biochemistry and molecular biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Angela M MitchellGene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Matthew L Hirsch
Chengwen Li
R Jude Samulski
University of North Carolina at Chapel Hill · US

Funding

VECTOR AND MOLECULAR BIOLOGY COREP01HL112761 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MONAHAN, PAUL E · 2013 to 2017
$11.3M
Training & EducationU54AR056953 · NIAMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SAMULSKI, RICHARD J · 2008 to 2012
$7.1M
Molecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7M
Rational and Combinatorial Engineering of AAV VectorsR01AI072176 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIRSCH, MATTHEW LOUIS, SAMULSKI, RICHARD J · 2008 to 2017
$3.7M
AAV Gene Therapy for AAT DeficiencyR01DK084033 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, CHENGWEN · 2009 to 2016
$2.2M
CTL response to AAV VectorR01AI080726 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, CHENGWEN, SAMULSKI, RICHARD J · 2010 to 2014
$1.8M
Overcoming our clinical complications: AAV vector design for the treatment of DMDR01AR064369 · NIAMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIRSCH, MATTHEW LOUIS, SAMULSKI, RICHARD J · 2013 to 2017
$1.6M
NHLBI NIH HHS 1P01HL112761NHLBI NIH HHS P01 HL112761NIAID NIH HHS 1R01AI080726NIAID NIH HHS 5R01AI072176NIAID NIH HHS 5T32-AI007419NIAID NIH HHS R01 AI072176NIAID NIH HHS R01 AI080726NIAID NIH HHS T32 AI007419NIAMS NIH HHS 1R01AR064369NIAMS NIH HHS 5U54AR056953NIAMS NIH HHS R01 AR064369NIAMS NIH HHS U54 AR056953NIDDK NIH HHS 5R01DK084033NIDDK NIH HHS R01 DK084033
6 · The paper itself

Abstract

Tripartite motif proteins are important viral restriction factors and affect processes ranging from uncoating to transcription to immune signaling. Specifically, the promyelocytic leukemia protein (TRIM19; also called PML) is a viral restriction factor inhibiting processes from uncoating to transcription to cell survival. Here we investigated PML's effect on adeno-associated virus (AAV), a parvovirus used for gene delivery. Although dependovirus (AAV) and autonomous parvovirus (minute virus of mice) replication centers can colocalize with PML, PML's functional effect on parvoviruses is unknown. Using PML knockout mice, we determined that PML knockout enhances recombinant AAV2 (rAAV2) transduction at a range of vector doses in both male and female mice. In fact, male and female PML knockout mice exhibited up to 56-fold and 28-fold increases in transduction, respectively. PML inhibited several rAAV serotypes, suggesting a conserved mechanism, and organ specificity correlated with PML expression. Mechanistically, PML inhibited rAAV second-strand DNA synthesis, precluding inhibition of self-complementary rAAV, and did not affect the prior steps in transduction. Furthermore, we confirmed the effect of human PML on rAAV transduction through small interfering RNA (siRNA)-mediated knockdown in HuH7 cells and determined that the highest level of inhibition was due to effects of PML isoform II (PMLII). Overexpression of PMLII resulted in inhibition of second-strand synthesis, vector production, and genome replication. Moreover, wild-type AAV2 production and infectivity were also inhibited by PMLII, demonstrating a PML interaction with wild-type AAV. These data have important implications for AAV-mediated gene therapy. Additionally, PMLII inhibition of AAV second-strand synthesis and replication, which are processes necessary for all parvoviruses, suggests implications for replication of other parvoviruses.

Indexed as

DNA ReplicationAnimalsCell LineDependovirusDown-RegulationFemaleHumansMaleMice, 129 StrainMice, KnockoutNuclear ProteinsParvoviridae InfectionsPromyelocytic Leukemia ProteinRecombination, GeneticTranscription FactorsTumor Suppressor ProteinsNuclear ProteinsPML protein, humanPromyelocytic Leukemia ProteinTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID24198403
PMCPMC3911643
OpenAlexW1984378665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.